Brighton and Sussex University Hospitals, Brighton, UK.
Eur Radiol. 2012 Mar;22(3):579-87. doi: 10.1007/s00330-011-2304-2. Epub 2011 Oct 13.
To conduct an economic analysis (EA) of coronary calcium scoring (CCS) using a 0 score, as alternative to stress electrocardiography (sECG) in diagnosing coronary artery disease (CAD).
A decision tree was constructed to compare four strategies for investigation of suspected CAD previously assessed in the formulation of clinical guidelines for the United Kingdom (UK) to two new strategies incorporating CCS. Sensitivity (96%; 95% CI 95.4-96.4%) and specificity (40%; 95% CI 38.7-41.4%) values for CCS were derived from a meta-analysis of 10,760 patients. Other input variables were obtained from a previous EA and average prices for hospital procedures in the UK. A threshold of £30,000/Quality-adjusted Life Year (QALY) was considered cost-effective.
Using net monetary benefit calculations, CCS-based strategies were found to be cost-effective compared to sECG equivalents at all assessed prevalence of CAD. Using CCS prior to myocardial perfusion scintigraphy (MPS) and catheter angiography (CA) was found to be cost-effective at pre-test probabilities (PTP) below 30%.
Adoption of CCS as an alternative to sECG in investigating suspected stable angina in low PTP population (<30%) would be cost-effective. In patients with PTP of CAD >30%, proceeding to MPS or CA would be more cost-effective than performing either CCS or sECG.
Coronary calcium scoring (CCS) is useful for assessing coronary artery atherosclerosis It can be performed with multi-detector CT, which is now widely available It plays a role in excluding disease in suspected stable angina Our study assesses its role in this setting as alternative to stress-ECG Adoption of CCS as an alternative to sECG could prove cost-effective.
通过对冠状动脉钙化评分(CCS)的零评分进行经济分析(EA),替代应激心电图(sECG)来诊断冠状动脉疾病(CAD)。
构建决策树以比较之前在英国(UK)临床指南制定中评估的四种疑似 CAD 调查策略,以及两种纳入 CCS 的新策略。CCS 的灵敏度(96%;95%CI 95.4-96.4%)和特异性(40%;95%CI 38.7-41.4%)值源自对 10760 例患者的荟萃分析。其他输入变量来自之前的 EA 和英国医院程序的平均价格。将 30000 英镑/质量调整生命年(QALY)的阈值视为成本效益。
使用净货币收益计算,与 sECG 等效相比,基于 CCS 的策略在所有评估的 CAD 患病率下都具有成本效益。在心肌灌注闪烁成像(MPS)和导管血管造影(CA)之前使用 CCS,在预测试概率(PTP)低于 30%时被认为具有成本效益。
在低 PTP 人群(<30%)中,采用 CCS 替代 sECG 来调查疑似稳定型心绞痛具有成本效益。在 CAD 的 PTP >30%的患者中,进行 MPS 或 CA 比进行 CCS 或 sECG 更具成本效益。
冠状动脉钙化评分(CCS)可用于评估冠状动脉粥样硬化。它可以使用现在广泛应用的多探测器 CT 进行。它在疑似稳定型心绞痛中发挥着排除疾病的作用。我们的研究评估了其在这种情况下替代 sECG 的作用。采用 CCS 替代 sECG 可能具有成本效益。